Focus Stocks
Up/Downgrades
Published on Monday, 25 June 2012 08:07 Written by Danny Miller
New York, June 25th (TradersHuddle.com) – Following are some of the upgrades and downgrades before the market open.
Arena Pharmaceuticals (NASDAQ: ARNA) was downgraded to Market Perform from Outperform at BMO Capital.
Ball Corp. (NYSE: BLL) was downgraded to a Neutral from Overweight at JPMorgan.
Elster (NYSE: ELT) was downgraded to a Hold from Buy at Wunderlich. The firm set its target price at $18.
Greif (NYSE: GEF) was downgraded to a Neutral from Overweight at JPMorgan.
Halliburton (NYSE: HAL) was downgraded to a Neutral from Buy at Pritchard.
Netflix (NASDAQ: NFLX) was upgraded to a Neutral from Sell at Janney Capital Markets.
Research In Motion (NASDAQ: RIMM) was downgraded to Underweight from Equal Weight at Morgan Stanley.
Related Articles
- Ball Corporation Completes Offering of Senior Notes Due 2023
- Ball Corporation to Present at Goldman Sachs Basic Materials Conference
- Ball Corporation to Present at Barclays High Yield Bond and Syndicated Loan Conference
- Ball Aerospace Wins Contract to Build Air Quality Sensor for KARI
- Ball Aerospace-Built Radarsat-1 Far Outlives Mission Expectations
- Ball Corporation Prices $1 Billion of Notes
- Updated Time for Ball Corporation Presentation at Wells Fargo Securities Industrial and Construction Conference
- Ball Corporation Announces Public Offering of Senior Notes
- Ball Corporation Announces Tender Offer and Consent Solicitation
- Listen Live to Ball Corporation Presentation at Wells Fargo Securities Industrial and Construction Conference
Related Partner Headlines
- 4 Stocks Pushing The Consumer Non-Durables Industry Lower - TheStreet.com
- Top 4 Mid-Cap Stocks In The Packaging & Containers Industry With The Highest EPS - Benzinga
- Arena Pharmaceuticals Inc. (ARNA): Today's Featured Drugs Winner - TheStreet.com
- Arena Pharmaceuticals Inc. Stock Sell Recommendation Reiterated (ARNA) - TheStreet.com
- Arena Pharma Sinks Under Weight Of Vivus' Troubles - TheStreet.com
- UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT on Arena Pharmaceuticals - Benzinga
- Vivus Weight-Loss Drug Launch In Early Trouble - TheStreet.com
- Arena Pharmaceuticals Inc. (ARNA): Today's Featured Health Care Laggard - TheStreet.com
- Vivus Weight-Loss Drug's Failing Math - TheStreet.com
- Ball Aerospace, B612 Foundation in Deal for Imaging Sensors for Sentinel Mission - Benzinga
JIM CRAMER wants to work for YOU. JIM does the research -- YOU get email alerts each time he trades. JIM provides access to his actual portfolio -- YOU can use it to guide your portfolio strategy.
Try Jim's Action Alerts PLUS for FREE!
TradersHuddle Search
|
Stock Search: |
|
Site Search: Loading
|
Recent Trading Ideas
Latest Partner Headlines
Stock Market
Loading
